Acorda Therapeutics Recognized By National Organization For Rare Disorders For Contribution To Treatment Of Multiple …

Acorda Therapeutics Recognized By National Organization For Rare Disorders For Contribution To Treatment Of Multiple …
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced the National Organization for Rare Disorders (NORD) is recognizing the Company for its efforts to develop therapies for rare diseases. Earlier this year, Acorda received approval from the U.S. Food and Drug Administration (FDA) for AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, the first therapy to improve walking in people with …

Read more on Medical News Today

More Meth Drug Addiction Info:

• Fda Commissioner Dr. Margaret Hamburg Talks Abo…
• Improving Transparency at the Food and Drug Administration: We …
• Drug Regulators, FDA, Publish Draft Guidance for Industy and FDA …
• FDA to investigate skin creams for mercury « Usa Health & Medicine …
• Tria Approved by FDA | Curing Acne – Quick Acne Relief
• Carcinoid & Neuroendocrine Tumor Patients Invited to FDA Public …
• Shire Receives 2010 Corporate Award From the National Organization …
• FDA to Take Up Major Enforcement Action Against Cosmetics …
• New York Biotechnology Association to Honor Acorda Therapeutics …
• Allen honored for research on rare childhood disease